ONS-5010 demonstrated statistically significant results in the treatment of patients with wet age-related macular degeneration, according to a press release from Outlook Therapeutics.
The phase 3 NORSE TWO safety and efficacy trial, evaluating ONS-5010/Lytenava (bevacizumab-vikg) compared with Lucentis (ranibizumab, Genentech), enrolled 228 patients with wet AMD. The primary endpoint was the proportion of patients who gained at least 15 letters in best corrected visual acuity at 11 months, the release said, while the secondary endpoint was the mean change in BCVA through 11 months.
For the